Cargando…

Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data

OBJECTIVE: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting. MATERIALS AND METHODS: A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aslaner Ak, Müzeyyen, Gedük, Ayfer, Acar, İbrahim Halil, Polat, Merve Gökçen, Sunu, Cenk, Bolaman, Ali Zahit, Hacıbekiroğlu, Tuğba, Güvenç, Birol, Ertop, Şehmus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240155/ https://www.ncbi.nlm.nih.gov/pubmed/36799095 http://dx.doi.org/10.4274/tjh.galenos.2023.2022.0437

Ejemplares similares

Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Efficacy and Adverse Events
por: Bolaman, Ali Zahit, et al.
Publicado: (2021)

The relationship between red cell distribution width and prognostic scores in myelodysplastic syndrome
por: Turgutkaya, Atakan, et al.
Publicado: (2022)

Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study
por: Acar, Ibrahim Halil, et al.
Publicado: (2022)

The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience
por: Açar, İbrahim Halil, et al.
Publicado: (2023)

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
por: Açar, İbrahim Halil, et al.
Publicado: (2023)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis
por: Raimbault, Anna, et al.
Publicado: (2016)

Discontinuation of the renin–angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes
por: Pavlidis, George, et al.
Publicado: (2021)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
por: Mersin, Sinan, et al.
Publicado: (2021)

Spontaneous Remission in Paroxysmal Nocturnal Hemoglobinuria: An Extremely Rare Case
por: Mehtap, Özgür, et al.
Publicado: (2022)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

Efficacy of convalescent plasma according to blood groups in COVID-19 patients
por: HACIBEKİROĞLU, Tuba, et al.
Publicado: (2021)

Auer Rods Are Not Seen in Non-Neoplastic Cells
por: Yavaşoğlu, İrfan, et al.
Publicado: (2016)

Sweet Syndrome Associated with Ixazomib
por: Yavaşoğlu, İrfan, et al.
Publicado: (2021)

Limb gangrene: The first sign of essential thrombocythemia
por: Bolaman, Ali Zahit, et al.
Publicado: (2020)

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
por: Horváth-Puhó, Erzsébet, et al.
Publicado: (2018)

Inclusion Body in a Leukocyte in Crimean-Congo Hemorrhagic Fever
por: Bolaman, Zahit, et al.
Publicado: (2015)

Leukemia and rosiglitazone
por: Yavasoglu, Irfan, et al.
Publicado: (2016)

Multiple Myeloma and Alkaline Phosphatase
por: Yavaşoğlu, İrfan, et al.
Publicado: (2015)

Eyebrow Whitening Induced by Imatinib
por: Yavasoglu, Irfan, et al.
Publicado: (2020)

Chlorella-induced thrombocytopenia
por: Yavasoglu, Irfan, et al.
Publicado: (2018)

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome
por: Garelius, H. K. G., et al.
Publicado: (2016)

COVID-19-associated Evans syndrome: A case report and review of the literature
por: Turgutkaya, Atakan, et al.
Publicado: (2022)

Cabot ring-like faggot cells in acute promyelocytic leukemia
por: Yavasoglu, Irfan, et al.
Publicado: (2022)

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes
por: Elvarsdóttir, Edda María, et al.
Publicado: (2019)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Rheumatoid Arthritis and Anti-Thyroid Antibodies
por: Yavasoglu, Irfan, et al.
Publicado: (2009)

Bone and Bone Marrow Involvement in Sarcoidosis
por: Sargın, Gökhan, et al.
Publicado: (2014)

Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients
por: Gonçalves, Ana Cristina, et al.
Publicado: (2021)

Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia
por: Parisi, Sarah, et al.
Publicado: (2021)

Excellent Interim Treatment Response with Polatuzumab Vedotin
por: Mehtap, Özgür, et al.
Publicado: (2020)

Fertility-Preserving Treatment Options in Patients with Malignant Hematological Diseases
por: Küçük, Mert, et al.
Publicado: (2012)

Knowledge, Attitudes, and Practices of Hematologists Regarding Fertility Preservation in Turkey
por: Küçük, Mert, et al.
Publicado: (2013)

Masquerading of COVID-19 Infection as Primary Mediastinal Large B-Cell Lymphoma
por: Bolaman, Ali Zahit, et al.
Publicado: (2021)

Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor
por: Nautiyal, Kirtan, et al.
Publicado: (2014)

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Penile Ulcer Atra Related in Patient with Acute Promyelocytic Leukemia
por: Yavasoglu, Irfan, et al.
Publicado: (2012)

Serum Bcl-2 Levels in Patients with β-Thalassemia Minor: A Pilot Study
por: Yavaşoğlu, İrfan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_47m25oa87fdsff1nauajohl0kc